We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
1
Jun 2026
A major UK study has found that while most middle-aged and older adults experience low levels of anxiety, a small group of people with higher autistic traits are much more likely to report that their anxiety worsens as they age.
1
Jun 2026
With obesity now affecting more than 40% of U.S. adults and fueling rising rates of heart disease, a new scientific statement from the American Heart Association calls for a comprehensive treatment approach that puts physical activity front and center.
1
Jun 2026
Researchers from Trinity College Dublin, St James's Hospital, and collaborating institutions have carried out the most comprehensive review to date of tools used to estimate breast cancer risk in women with a family history of the disease.
1
Jun 2026
The combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence by 49 percent, a new study shows.